Guilin Sanjin(SZ:002275)2025-05-17 03:26Inventory Management - The company has upgraded its inventory management system, utilizing a BI intelligent analysis system and a professional data analysis team to balance market demand dynamics and cost control [1] - The overall inventory level has significantly decreased compared to the same period last year, maintaining a healthy inventory cycle of 1.5 to 2 months [1] Product Growth Potential - The growth trend for the company's second and third-line products is positive, with specific products like the Hejia Danchuan capsule expected to maintain last year's growth rate [1] - The Xuanyunning series has surpassed 100 million in sales in 2021, aiming for double-digit growth this year [1] - Other products, such as Shuyanquing spray and Fufang Ganmaoling granules, are also expected to maintain high growth rates [1] Dividend Policy - The company has consistently implemented a cash dividend policy, proposing a cash dividend of 3.5 yuan per 10 shares for 2024, totaling 206 million yuan [2] - The dividend policy is expected to remain stable unless there are special funding needs [2] Biopharmaceutical Development - Biopharmaceuticals are a key part of the company's dual strategy, facing high investment and risk, with the industry currently experiencing a downturn [2] - The company is optimizing its R&D pipeline, focusing on projects with promising clinical data, such as the BC006 monoclonal antibody injection, which is nearing the completion of Phase I clinical trials [2] - Efforts are being made to control costs and expenses while seeking partnerships in the biopharmaceutical sector [2]